A Highly Experienced Team committed to alleviating pain and suffering from heart disease – heart attacks and heart failure
Our technology delivers 10X more adult stem cells, intravenously, to the damaged heart, without heart catheterization. It enhances repair and restores heart function, more efficiently than current heart repair clinical regenerative medicine protocols.
TargaCell is a Chicago-based biotech, dedicated to repairing damaged hearts, improving their function, preventing progression to heart failure and restoring the quality of life for people with heart disease.
Leadership
The TargaCell Corporation Leadership Team
Catherine Phillips,
PhD
CEO/CSO
Robin McWherter,
CMRT
Chief, Research Operations and Facilities
David Ellison,
CPA
CFO
Susan Ball-Kell,
DVM, PhD
Director, Pathology, Pharmacology, and Toxicology
Matthew Raymond,
PhD, MBA
VP Business Development and Regulatory
Mark Pittenger,
PhD
Chief Technology Officer Stem Cell Biology KOL
Patrick D. Lamb,
JD
General Counsel
Board of Directors
The TargaCell Corporation Board of Directors
Business Advisor
The TargaCell Corporation Business Advisor
Michael Beaubaire,
MD, MBA
